Combined Screening with QF-PCR (Delfia)
What is this test?
Combined Screening with QF-PCR (Delfia) is an advanced prenatal screening test performed during early pregnancy to assess the risk of chromosomal abnormalities in the baby. It combines maternal serum screening using the Delfia platform with QF-PCR genetic analysis for improved accuracy and faster confirmation.
Why is this test done?
This test helps evaluate the risk of conditions such as:
- Down Syndrome (Trisomy 21)
- Edwards Syndrome (Trisomy 18)
- Patau Syndrome (Trisomy 13)
- Sex chromosome abnormalities
It is commonly recommended during the first trimester of pregnancy.
Sample Required
- Maternal Blood Sample
- Prenatal sample for QF-PCR analysis (if advised by clinician)
Benefits of the Test
- Early prenatal risk assessment
- High sensitivity screening
- Rapid chromosomal analysis
- Reliable Delfia-based biochemical testing
- Supports informed pregnancy care decisions
When is the test recommended?
Usually between:
- 11 to 13 weeks + 6 days of pregnancy
Preparation
- No fasting required
- Clinical history and ultrasound details may be needed
Reporting Time
- As per laboratory protocol / typically within a few days
Note
This is a screening test and not a final diagnostic confirmation. Further consultation with a healthcare professional may be recommended based on results.
